MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

EscharEx® Phase III study protocol:FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry ...

Related Keywords

Yavne ,Hamerkaz ,Israel ,Japan ,Japanese ,Assaf Segal ,Trima Pharma ,Ofer Gonen ,Monique Kosse ,Hani Luxenburg ,Strata Skin Sciences Nasdaq ,Drug Administration ,Sun Pharmaceuticals ,Committee For Medicinal Products Human Use ,Company On Linkedin ,Kaken Pharmaceutical Co ,European Medicines Agency ,European Medicine Agency ,Company Board Of Directors ,Nasdaq ,Mediwound Ltd ,Taro Pharmaceuticals Nasdaq ,Exchange Commission ,Escharex Phase ,Recent Developments ,Medicinal Products ,Human Use ,Kaken Pharmaceutical ,Taro Pharmaceuticals ,Strata Skin Sciences ,Medison Biotech ,Mediwound Board ,Eastern Time ,Quarterly Reports ,Operating Activities ,Investment Activities ,Financing Activities ,